Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fosigotifator in Major Depressive Disorder
NCT06618118Phase 1Terminated
- Sponsor
- AbbVie Inc.
- Start
- Oct 2024
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in major depressive disorder (MDD) comparing Fosigotifator with Placebo (2 arms). Primary endpoint: Adverse Events at 114 days. Started Oct 2024; status: terminated.
02
Drugs
fosigotifator
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT06618118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06618118.